| GTO ID | GTC2890 |
| Trial ID | NCT05192174 |
| Disease | Solid Tumor |
| Altered gene | GM2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | NIB101 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An Open-Label Non-Randomized Phase 1 Dose Escalation and Dose Expansion Study of NIB101 in Participants With Advanced Solid Tumors |
| Year | 2022 |
| Country | Japan |
| Company sponsor | Noile-Immune Biotech, Inc |
| Other ID(s) | NIB101-01 |
| Cohort 1 | |||||||||
|
|||||||||